written on 12.05.2014

Shire pledges $260M-plus in deal for liver-focused Lumena


Lumena won't be going through with that $75 million IPO after all. Shire is scooping up the company and its two development programs for rare liver diseases for $260 million in cash along with an undisclosed slate of milestones.

Latest Reports